We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02678689
Recruitment Status : Completed
First Posted : February 10, 2016
Last Update Posted : May 20, 2022
Information provided by (Responsible Party):
BioMarin Pharmaceutical

Brief Summary:
This Phase 2 open-label, multicenter study will evaluate the safety, tolerability, and efficacy of BMN 190 intracerebroventricular (ICV) administration every other week (qow) for a period of 144 weeks, in patients with CLN2. The study is designed to assess disease progression in CLN2 patients treated with BMN 190 compared to natural history data from untreated historical controls.

Condition or disease Intervention/treatment Phase
Jansky-Bielschowsky Disease Batten Disease Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 CLN2 Disease CLN2 Disorder Biological: BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1) Device: Intraventricular access device Phase 2

Detailed Description:
BMN 190 is a recombinant form of human tripeptidyl peptidase 1 (TPP1), the enzyme deficient in patients with CLN2 diseases (also known as classical late-infantile CLN2, cLINCL, or Jansky-Bielschowsky disease), a form of Batten Disease. As an enzyme replacement therapy (ERT), BMN 190 is designed to help restore TPP1 enzyme activity. BMN 190 is designed to reduce the progressive, pathologic accumulation of lysosomal storage material. 190-203 is a Phase 2 open-label, multicenter study that will evaluate the safety, tolerability, and efficacy of BMN 190 in pediatric patients < 18 years of age with CLN2 disease. Study drug dosing will be determined by the patient's age and administered via intracerebroventricular (ICV) infusion every other week (qow), for a duration of 144 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease
Actual Study Start Date : February 2016
Actual Primary Completion Date : November 1, 2021
Actual Study Completion Date : April 20, 2022

Arm Intervention/treatment
Experimental: BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)
An age-appropriate dose of BMN 190 administered via intracerebroventricular (ICV) infusion every other week (qow) for a duration of 144 weeks.
Biological: BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)
Other Names:
  • recombinant human tripeptidyl peptidase-1 (rhTPP1)
  • cerliponase alfa

Device: Intraventricular access device
Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.

Primary Outcome Measures :
  1. Incidence and severity of adverse events as assessed by CTCAE v 4.0 [ Time Frame: Up to 144 weeks ]
  2. Change in the 0-6-point Motor/Language (ML) score on the Hamburg CLN2 rating scale [ Time Frame: Up to 144 weeks ]
  3. Immunogenicity of BMN 190 in CSF and serum [ Time Frame: Up to 144 weeks ]

Secondary Outcome Measures :
  1. Change in the total Hamburg CLN2 rating scale [ Time Frame: Up to 144 weeks ]
  2. Change in clinical laboratory tests [ Time Frame: Up to 144 weeks ]
  3. Change in CSF and Plasma laboratory parameters [ Time Frame: Up to 144 weeks ]
  4. Vital signs [ Time Frame: Up to 144 weeks ]
  5. Physical examination [ Time Frame: Up to 144 weeks ]
  6. Neurological examinations [ Time Frame: Up to 144 weeks ]
  7. Electrocardiogram (ECG), 3 or 5-lead, 12-lead [ Time Frame: Up to 144 weeks ]
  8. Change in Brain Volumes as Assessed by Cranial Magnetic Resonance Imaging (MRI) [ Time Frame: Up to 144 weeks ]
  9. Assess time to disease manifestation for asymptomatic patients [ Time Frame: Up to 144 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   0 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Enrollment over the age of 2 years is complete.

Inclusion Criteria:

  • Diagnosis of CLN2 disease as determined by TPP1 enzyme activity (dried blood spot) in the fibroblasts and leukocytes available at Screening
  • Quantitative clinical assessment of the Hamburg motor-language aggregate score 3-6 at Screening on CLN2 disease motor-language scale, as defined in the Ratings Assessment Guideline
  • < 18 years of age at the time of informed consent
  • Written informed consent from parent or legal guardian and assent form subject, if appropriate
  • Males and females who are of reproductive age should practice true abstinence, defined as no sexual activity, during the study and for 6 months after the study has been completed (or withdrawal from the study). If sexually active and not practicing true abstinence, males and females of reproductive age must use a highly effective method of contraception while participating in the study.
  • Ability to comply with protocol required assessments (ICV implantation, drug administration, laboratory sample collection, EEG, ECG, MRI, etc.)

Exclusion Criteria:

  • Presence of another inherited neurological disease, e.g., other forms of CLN or seizures unrelated to CLN2 disease (patients with febrile seizures may be eligible)
  • Presence of another neurological illness that may have caused cognitive decline (e.g., trauma, meningitis, hemorrhage) or interference with disease rating (autism) before Screening
  • Presence of percutaneous feeding tube placement prior to enrollment
  • Has received stem cell, gene therapy, or ERT
  • Presence of contraindications for neurosurgery (e.g., congenital heart disease, severe respiratory impairment, or clotting abnormalities)
  • Presence of contraindications for MRI scans (e.g., cardiac pacemaker, metal fragment or chip in the eye, aneurysm clip in the brain)
  • Episode of generalized motor status epilepticus within 4 weeks before the First Dose visit
  • Severe infection (e.g., pneumonia, pyelonephritis, or meningitis) within 4 weeks before the First Dose visit (enrollment may be postponed)
  • Presence of ventricular abnormality (hydrocephalus, malformation)
  • Presence of ventricular shunt
  • Has known hypersensitivity to any of the components of BMN 190
  • Has received any investigational mediation within 30 days before the first infusion of study drug or is scheduled to receive any investigational drug other than BMN 190 during the course of the study
  • Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with the protocol required testing or procedures or compromise the subject's well being, safety, or clinical interpretability
  • Pregnancy any time during the study; a female subject judged by the investigator to be of childbearing potential will be tested for pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02678689

Layout table for location information
United States, Ohio
Nationwide Children's Hospital
Columbus, Ohio, United States, 43205
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany, 20246
Children's Hospital Bambino Gesù,IRCCS
Rome, Piazza, Italy, 00165
United Kingdom
Great Ormond Street Childrens Hospital
London, United Kingdom, WC1N 3JH
Sponsors and Collaborators
BioMarin Pharmaceutical
Layout table for investigator information
Study Director: Medical Director, MD BioMarin Pharmaceutical
Layout table for additonal information
Responsible Party: BioMarin Pharmaceutical
ClinicalTrials.gov Identifier: NCT02678689    
Other Study ID Numbers: 190-203
First Posted: February 10, 2016    Key Record Dates
Last Update Posted: May 20, 2022
Last Verified: May 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuronal Ceroid-Lipofuscinoses
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Lipid Metabolism Disorders
Metabolic Diseases